James Barrow (Trades, Portfolio) is executive director of Dallas-based investment firm Barrow, Hanley, Mewhinney & Strauss, the lead portfolio manager for the Vanguard Windsor II and Selected Value Funds.The firm invest in equities with below-market price-to-earnings ratios, below-market price-to-book ratios, and above-market dividend yields. For the 10-year period ending 3/31/2010, the Selected Value Funds averaged 9.33% a year, while the market had negative returns.Â
Pfizer (PFE) is one of James Barrow's top ten holdings. Last quarter, his firm held 55,080,222 shares of the company. The following chart below shows his holding history in the company.
Pfizer Inc. is a research-based, global biopharmaceutical company. The company is involved in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as many of the world’s best-known consumer healthcare products. Last quarter, Pfizer reported better-than-expected results with adjusted EPS of $0.51 versus $0.49 consensus and revenues of $10.9 billion versus $10.72 billion consensus. Commenting on the results, the company's Chairman and CEO Ian Read said:
"We began the year with good performance on both the top and bottom line and I believe the company is well-positioned in terms of in-line products, recent product launches, geographic reach and product pipeline."
However, Pfizer lowered its guidance for the full year 2015. The company now expects full-year adjusted earnings of $1.95 to $2.05 per share versus earlier expectations of $2.00 to $2.10, on revenue of $44.0 billion to $46.0 billion versus earlier expectations of $44.5 billion to $46.5 billion. However, one should note that this guidance change is solely a result of negative impact of recent currency movements and the company's operating outlook has actually improved compared to the beginning of the year.
Pfizer's share price has remained rangebound over the last two years. During the last few years, the company has lost significant revenue due to loss of exclusivity (patent expiry) and co-promote expiries from several high margin products like Lipitor Enbrel in Canada and the US, and the loss of Spiriva. The company was, however, able to maintain its operating margins by cutting costs. Over the last four years, Pfizer have taken approximately $5.5 billion out of from operating expenses. Management expects these ongoing expense reductions efforts to continue over the next few years.
In order to enhance shareholder returns during this tough period, Pfizer has returned about $64 billion to shareholders with share repurchases and dividends over the last four years. The company expects to return another $13 billion to shareholders in FY2015. Management expects FY2015 revenues will see a negative impact of $3.5 billion from loss of exclusivity on certain products and of $2.8 billion due to adverse changes in foreign exchange. They will be partially offset by nearly $2 billion of anticipated operational revenue growth in certain products like Eliquis, Xeljanz, Prevnar 13 Adult, Trumenba, Inlyta, Xalkori and Nexium 24HR.
Pfizer is trading at 16.5 times it FY2015 EPS. The company has a forward annual dividend yield of 3.30%. In the near term, patent expiry and forex headwind are expected to adversely affect the company's topline growth. However, the real promise for Pfizer's shareholders lies in the strength of its late and mid-stage pipeline, which will help it grow its revenues in the medium term. Meanwhile the company's high dividend yield, cost cutting initiatives, share repurchases and low valuations are expected to provide support to the shares.
